Global Influenza Vaccines Market to surpass US$ 6.0 Billion by 2025

The Global Influenza Vaccines Market, by Vaccine Type (Trivalent Vaccines and Quadrivalent Vaccines), by Virus Type (Influenza Virus A and Influenza Virus B), by Age Group (Pediatrics and Adults) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) estimated to be valued at US$ 3,991.4 billion in 2017, and is projected to exhibit a CAGR of 4.4% over the forecast period (2018 – 2026) as highlighted in a new report published by Coherent Market Insights.

Rising pipeline product to come up with new vaccine product as a part of key organic strategies by market players. For instance, 2017, Seqirus’s FLAUD, first and only adjuvant-based trivalent influenza vaccine, received MHRA approval against influenza virus in older aged people (adults aged 65 and above). In same year, Seqirus entered in the U.S market with its influenza vaccine portfolio, with over 50 million doses for protection against seasonal influenza of 2017-2018. The portfolio includes FLAUD, FLUCELVAX QUADRIVALENT, AFLURIA QUADRIVALENT, AFLURIA, and FLUVIRIN. Moreover, in 2017, FluGen, Inc., received US$ 14.4 million by Department of Defense for evaluating Universal Flu Vaccine, RedeeFlu, of Mismatched Strains. In Sep 2017, Novavax initiating phase1/2 clinical trials for nanoparticle seasonal influenza vaccine in older adults. In April 2018, BiodVax Pharmaceuticals LTD., started enrollment of patients for phase 2 clinical trials for universal flu vaccine candidate, M-001.

Browse Market Data 32 Tables and 30 Figures spread through 150 Pages and in-depth TOC on "Influenza VaccinesMarket, by Vaccine Type (Trivalent Vaccines and Quadrivalent Vaccines), by Virus Type (Influenza Virus A and Influenza Virus B), by Age Group (Pediatrics and Adults) and by Region - Global Forecast to 2026”

To know the latest trends and insights related to Influenza Vaccines market, click the link below:

Increasing prevalence of seasonal influenza in pediatric population is propelling demands for development of new vaccines. Influenza is estimated to infect 5% and 10% of adults and 20 to 30% of children. Moreover, companies are engaged in producing vaccines through innovative technologies such as egg-based, cell-based, and recombinant-based product for reducing the gap between demand and supply. Furthermore, increasing awareness and initiatives to increase the vaccine coverage is helping in market growth. The 2017 – 2018 recommendations guidelines by the Advisory Committee on Immunization Practices (ACIP) mentions routine annual influenza vaccination for everyone aged older than 6 months. However, high cost of vaccine development is expected to hinder growth of the market over the forecast period.

Key takeaways of the Influenza Vaccines Market:

The global influenza vaccines market is expected to expand at a CAGR of 4.4% during the forecast period (2018 – 2026), owing to increasing R&D activities of market players.

Trivalent vaccine is expected to dominate vaccine type segment, owing to more number of products

Influenza type A virus segment is expected to be predominant, owing to increasing prevalence of type A based infection

Pediatric being more susceptible to influenza virus is expected to lead age group segment

Some of the major players involved in global influenza vaccines market include Seqirus Vaccines Limited, GlaxoSmithKline plc